Comparative Pharmacology
Head-to-head clinical analysis: FLEXICORT versus LOCOID LIPOCREAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLEXICORT versus LOCOID LIPOCREAM.
FLEXICORT vs LOCOID LIPOCREAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FLEXICORT contains the active ingredient prednisolone, a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression, inhibition of phospholipase A2, and suppression of inflammatory mediators such as prostaglandins and leukotrienes.
Locoid Lipocream contains hydrocortisone butyrate, a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins (lipocortins), thereby inhibiting the release of arachidonic acid and subsequent synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production, reduces mast cell degranulation, and decreases vascular permeability.
Flexicort is not a recognized drug name in authoritative pharmacological databases. Please verify the correct generic name. Assuming hydrocortisone: Typical adult dose is 10-40 mg orally daily in divided doses or as a single morning dose. Route: oral. Frequency: once or twice daily.
Apply a thin layer to affected area twice daily. Maximum duration of continuous treatment: 4 weeks.
None Documented
None Documented
8–12 hours; clinical context: once-daily dosing maintains therapeutic levels, with steady-state achieved within 2–3 days.
Terminal elimination half-life: ~6-8 hours (hydrocortisone butyrate); clinical context: supports twice-daily dosing
Renal excretion of inactive metabolites accounts for 95% of elimination; biliary/fecal excretion is minimal at 5%.
Renal: ~1.5% as unchanged hydrocortisone butyrate and metabolites; Biliary/fecal: ~85% as metabolites
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid